Main article: Cancer treatment
2024
Axelfarma fined ₽513 million for selling a copy of a cancer drug
The Federal Antimonopoly Service of Russia recognized the pharmaceutical company AxelPharm as a violator of the law on protection of competition in the release of the generic anticancer drug Axitinib. As a result of the consideration of the case on October 25, 2024, the company was ordered to transfer to the budget income in the amount of ₽513 million received from illegal sales. Read more here.
The Russian original drug for the treatment of melanoma is included in the list of VEDs
The Commission of the Ministry of Health included the original drug "Nurdati," developed by scientists of the biotechnological company BIOCAD, in the list of vital and essential drugs (VED). This solution opens up access to innovative therapies for more than 550 patients. Biocad announced this on August 23, 2024. Nurdati is a monoclonal antibody drug created to treat patients with melanoma, including cases with metastases. Read more here.
MIPT will develop a drug for the treatment of lung cancer
The KRAS inhibitor-based drug designed by the Institute of Biophysics of the Future MIPT will be used as part of targeted cancer therapy for lung cancer. The drug substance meets all import substitution standards and will be tested in vitro by the end of 2024. MIPT announced this on August 19, 2024. Read more here.
Ozone Pharmaceuticals is building a plant for the production of cancer drugs in Russia for 3.5 billion rubles
The Group, Ozone Pharmaceuticals Russian the pharmaceutical manufacturer of the drugs, completed the first stage constructions of the production site "" in the Ozon Medica special economic zone. Representatives Togliatti of the Group reported this medical that to the portal Zdrav.Expert on July 30, 2024. According to them, the plant will have wide possibilities for the production of pharmaceutical forms, including the production of drugs of the maximum, fifth, toxicity category. More. here
Ministry of Health: 135 domestically produced cancer drugs registered in Russia
As of the beginning of 2024, 135 domestically produced drugs intended for the treatment of cancer were registered in Russia. Such data in mid-February 2024 was published by the Ministry of Health of the Russian Federation.
According to the Ministry of Health, construction and reconstruction of oncological dispensaries is underway in 13 regions. More than 16 thousand units of modern medical diagnostic and medical equipment were put into operation. Due to this, the availability of therapy for patients has been increased. In addition, more than 100 clinical trials of oncological drugs are being carried out in the Russian Federation. The development of outpatient treatment services continues.
 | Today, 534 outpatient cancer care centers have been created. We conducted almost 47 thousand telemedicine consultations and more than 330 thousand laboratory tests in reference centers, which allows us to form a common communication field for specialists, "says Russian Minister of Health Mikhail Murashko. |  |
In 2023, domestic pharmaceutical companies registered over 40 drugs for the treatment of cancer. The share of domestic cancer drugs in public procurement in physical terms by the beginning of 2024 is approaching 70%. In 2021-2022 The Ministry of Health of Russia conducted 229 clinical trials of drugs for treatment in the field of oncology and hematology.
The ministry, according to its head, faces large-scale tasks for the development and implementation of the latest domestic technologies for the diagnosis and treatment of cancer, the technical modernization of the service, and increasing the availability of medical care in the oncology profile in all regions of Russia, including new ones. It is said that often the selling price of Russian analogues of drugs is one and a half to two times lower than that of imported drugs.[1]
Russian scientists have learned to manage the properties of substances that can become the basis of drugs against a brain tumor
Scientists at NRNU MEPhI as part of an international scientific team have learned to manage the properties of pyridoquinazolines - substances that can become the basis of drugs against a brain tumor. The university announced this on March 13, 2024.
Most drugs are created, as a rule, by the method of practical selection of chemical compounds that exhibit the desired properties. But if you learn to "adapt" molecules to the molecular mechanisms of the disease, scientists would be able to develop drugs consciously, not just empirically.
Employees of the Laboratory of Chemoinformatics and Molecular Modeling of the Institute of Intelligent Cybernetic Systems of the NRNU MEPhI set themselves the task of learning how to manage the properties of chemical compounds that could become the basis of antitumor drugs, said co-head of the laboratory Alexander Shtil.
In collaboration with researchers at the University of Clermont-Ferrand (France), NRNU MEPhI scientists studied the properties of pyridoquinazolines, compounds that have proven themselves as active blockers of proteins of two families that are important for the viability of a dangerous tumor tumor - glioblastoma.
Proteins that are blocked by pyridoquinazolines drive gene transcription. Therefore, blocking transcription is a chance to kill glioblastoma, explained Alexander Shtil.
| | We found that a single chemical substitution in the pyridoquinazoline molecule alters the spectrum of target proteins: other targets are preferred, and the drug has new properties. Therefore, it will be possible to specifically choose a candidate from a series of "blanks" substances, "he said. | |
To solve this problem, co-head of the laboratory Sofia Borisevich and researcher Margarita Ilyina conducted large-scale theoretical calculations using methods of modern computational chemistry. They found out how it is possible to explain the "change of preferences" of the target protein, which means to control the mechanism of action of the candidate drug.
Experimental confirmation of the calculations was carried out by employees of the Institute of Bioorganic Chemistry. ACOD. M. M. Shemyakin and Yu. A. Ovchinnikov RAS. Using high-throughput molecular analysis methods, they examined the drug candidate's interactions with patients' glioblastoma cells.
Earlier, the authors of the study as part of an international scientific team established the possibility of extending the life of laboratory mice with a transplanted brain tumor, which were injected with the test compound (see doi.org/10.1038/s41556-022-00994-w).
2023
Russian biosimilars and generics against cancer occupied 60% of the total clinical research market in Russia
In 2023, for the first time in 5 years, starting from 2019, the number of clinical trials the Russian of biosimilars and generics bioequivalence oncology treatment for biosimilars reached 58%. This is almost 60% of the entire domestic market for antitumor developments. According to the analysis of the open data register of permits for conducting - clinical trials Ministry of Health RUSSIAN FEDERATION over the past two years, the number of trials of domestic biosimilars and generics against cancer has grown almost 2 times: From 32 in 2021 to 54 in 2023. In 2022, there were 49 of them. This was announced on February 8, 2024 by the company. OnkoTarget More. here
Mosunetuzumab is approved in Russia for the treatment of patients with relapsed or refractory follicular lymphoma
Roche announced that on November 14, 2023, the Ministry of Health of the Russian Federation approved mosunetuzumab (trade name Lansumio) as monotherapy in adult patients with relapsed or refractory follicular lymphoma (FL) who have previously received at least two lines of systemic therapy. Commercial availability of the drug in the Russian Federation is expected in mid-2024. Read more here.
Pharmsintez and Almazov Center agreed to cooperate to create a drug for the treatment of brain cancer
The portfolio company Rusnano - Pharmsintez and the Almazov Center agreed to cooperate in the creation of an innovative drug for the personalized diagnosis and treatment of malignant brain neoplasms. Rusnano reported this on June 14, 2023. Read more here.
Russian scientists have proposed a cure for double-acting cancer
The Russian scientists proposed an innovative approach to combat oncological diseases that will reduce severe side effects from treatment. They developed a prodrug Riboplatin for combination chemotherapy and photodynamic therapy based on Pt (IV) platinum and a photosensitizer (substances that increase the sensitivity of tissues to light exposure). The drug is controllably activated only in the malignant neoplasm zone under the influence of blue light, without affecting irradiated tissues, opening up opportunities for "point" chemical therapy. The design of the proposed prodrug solves the problem of toxicity and cellular resistance to traditional antitumor drugs. The research results are published in the scientific journal ACS Applied Materials & Interfaces. This was announced on April 25, 2023 by representatives. NPS MISiS More. here
Promomed invests 4.7 billion rubles in the production of drugs against cancer
Promomed Group of Companies initiates the construction of a workshop for the production of anticancer drugs in Saransk. The enterprise, in the creation of which 4.7 billion rubles will be invested, is planned to be located on the territory of the Biochemist plant. This was reported in March 2023 on the website of the Government of the Republic of Mordovia. Read more here.
Promomed has registered a new antitumor drug for the treatment of blood and bone marrow cancer
Bortezomib-Promomed used for multiple myeloma received marketing authorization. It is also prescribed to patients with mantle cell lymphoma, who have disease progression after several courses of treatment. Promomed announced this on March 9, 2023. Read more here.
Discovery of the first GMP laboratory of cellular technologies in Russia for the treatment of cancer
In January 2023, the Kaluga Region opened the first GMP laboratory of cellular technologies in Russia. It was launched at the A.F. Tsyba Medical Radiological Scientific Center. Read more here.
2022
Oncostar attracted 64 million rubles for testing a drug against breast cancer
The resident company OncostarSkolkovo conducted preliminary tests medicine for breast cancer human therapy and attracted 64 million from rubles private investors. The funds will allow the completion of the first phase of clinical trials by mid-2023. The product is developed on the basis of a genetically modified oncolytic, virus officially authorized for clinical trials. The Skolkovo Foundation announced this on December 14, 2022. More. here
R-Pharm and Pushchinsky Scientific Center will develop anticancer drugs
The R-Pharm Group of Companies and the Federal Research Center "Pushchinsky Scientific Center for Biological Research of the Russian Academy of Sciences" announced the start of joint work on the development of the latest generation of anticancer drugs. Scientific research will be carried out on the basis of a laboratory created with the financial and organizational support of R-Pharm within the framework of the New Medicine technological platform of the Ministry of Education and Science of Russia. R-Pharm announced this on December 5, 2022. Read more here.
A Norwegian company has created a drug that cures colorectal cancer. The first person has already recovered
On August 25, 2022, the Norwegian company Oncoinvent AS, which is in the clinical stage of the development of therapy with alpha emitters in various types of cancer, announced that the first patient with colorectal cancer in a phase 2A RAD-18-002 clinical trial received treatment with the candidate drug Radspherin. Read more here.
Ministry of Health of the Russian Federation registered a "universal" drug against cancer
At the end of June 2022, [[|Bayer]] received in Russia a registration certificate of the Ministry of [[|Health]] for the antitumor drug Vitrakvi (INN larotrectinib). Read more here.
Promomed has registered Lenalidomide-Promomed for the treatment of multiple myeloma
Promomed HA registered Lenalidomide for the treatment of multiple myeloma. The anticancer drug was the fourth in the company's oncoportfel. Read more here.
Amedart launched the production of drugs against cancer and HIV
The company "Amedart" in the special economic zone "Technopolice Moscow" has launched an import-substituting production of drugs, including for the treatment of HIV infection and oncological diseases. To create this production, the Industrial Development Fund provided the company with a preferential loan under the Development Projects program in the amount of 100 million rubles, which was announced on April 19, 2022. Read more here.
Launch of production of cancer drugs by BioJet
At the end of March 2022, it became known that the biotechnological production company BioJet (part of the PharmEco group) received residency in the special economic zone Technopolice Moscow. At the updated site, the company launches the production of drugs for targeted therapy of cancer. here.
Servier has applied for Ivosidenib for patients with acute myeloid leukemia and mutated cholangiocarcinoma IDH1
On 10 March 2022, Servier announced the submission to the European Medicines Agency (EMA) of a marketing authorization application for ivosidenib (tablets) for two indications: for first-line therapy in combination with azacitidine in patients with previously untreated acute myeloid leukemia (AML) with a mutation in the IDH1 gene who are contraindicated by intensive chemotherapy, as well as in patients with locally advanced or metastatic cholangiocarcinoma with a mutation in the IDH1 gene who have previously received treatment. The drug is an inhibitor of the mutant enzyme isocitrate dehydrogenase-1 (IDH1). Ivosidenib is a mutation-specific gene IDH1 targeted therapy drug declared for registration in Europe. Read more here.
Gilead recalls cancer treatment drug's indication due to deadly side effects
On January 14, 2022, the American biopharmaceutical company Gilead Sciences notified the regulator health care USA of its decision to voluntarily abandon the use of its drug Zydelig for the treatment of two types, namely cancer follicular lymphoma and small lymphocytic. leukemias More. here
2021: The head of the oncology department in Moscow received a suspended sentence for the resale of drugs for the treatment of cancer
In May 2021, the Lublin District Court of Moscow found the doctors of the oncological dispensary No. 5 of Moscow guilty of reselling drugs for the treatment of cancer. They got off with suspended sentences, although prosecutors asked for real ones. Read more here.
2020
9.2% increase in cancer drug sales, to $157.9 billion
In August 2021, analysts at Evaluate, which specialises in market research in the healthcare sector, released a report addressing the selling situation of drugs for cancer treatment. The volume of this market in 2020 reached $157.9 billion, an increase of 9.2% compared to 2019.
About 18% of the market for cancer drugs came from Bristol Myers Squibb. The group of leaders also included the following manufacturers: Roche, Merck, AstraZeneca and Novartis.
According to experts, in 2020, the COVID-19 coronavirus pandemic significantly changed the focus of the activities of leading pharmaceutical concerns in the world. Thus, 80% of clinical trials not related to the development of drugs against COVID-19 were suspended. Nevertheless, the fight against coronavirus did not lead to a fundamental change in the course of the pharmaceutical industry. Cancer drugs are still considered the most important developments, which provided industry enterprises with maximum turnover in 2020.
Sales of cancer drugs are growing and will continue to grow for several main reasons:
- the continued spread of cancer;
- unhealthy lifestyle of the population;
- an increase in the number of elderly people in the world;
- the emergence of new drugs on the market;
- growing demand for personalized drugs.
Keytruda, a drug intended for adjuvant therapy after surgical treatment in patients with melanoma with lymph node involvement, ranked second in sales across the pharmaceutical market. The revenue of Merck, the developer of this product, from its implementation in 2020 amounted to $14.38 billion. Also in the top 20 best-selling drugs were several other cancer developments (Opdivo, Avastin, Xtandi), whose annual sales are measured in billions of dollars.[2]
Cancer patients in Russia doubled their purchases of drugs with their own money
In 2020, drug sales antineoplastic in pharmacies Russia reached 5.2 billion rubles against 4.1 billion and 2.2 billion rubles a year and two years earlier, respectively. Such data are provided in a study prepared by the Pharmaceutical Bulletin industry publication and AlphaRM.
According to Vedomosti, in 2019, the implementation of the national project "Healthcare" began in the country. It involves the allocation of additional funding for the purchase of cancer drugs so that patients can receive them for free. Despite the increase in funding for purchases of cancer drugs from the state, the costs incurred by the residents of Russia themselves for these drugs have more than doubled in two years, the newspaper notes with reference to this study.
Director of Development of the Association of Oncologists of Russia Bahodur Kamolov pointed out to the publication that the state, as a rule, prefers cheap Russian generics, inferior in quality to original foreign drugs or foreign counterparts. If in public procurement, Russian drugs account for 63.7%, then in pharmacies - only 26%.
The publication notes that earlier patients with oncology could receive foreign drugs under the Campus Management compulsory medical insurance policy in private clinics. But since 2021, the authorities have limited the list of services that non-state medical institutions can provide to cancer patients. Therefore, patients who have the opportunity prefer to buy better foreign drugs in pharmacies on their own, Kamolov stated. The general director of the European Medical Center Andrei Yanovsky says the same. From 2022, new amendments to the rules for the provision of oncological care will come into force, which will further limit the ability of private clinics to treat patients with oncology through compulsory medical insurance.[3]
Cancer cell pH level becomes foundation of targeted drug delivery system in cancer therapy
On November 26, 2020, it became known that the scientific team of NUST MISIS, SibGMU and RNIMU named after N.I. Pirogova discovered that the efficiency of penetration of magnetic nanoparticles with a drug into the tumor depends on the pH level of its microenvironment (tissues). The results of the study will help create an oncotherapeutic "accurate hit" and are published in the international scientific journal Nanomedicine. Read more here.
ITMO scientists have found a way to non-invasively release drugs from polymer carriers inside cancer cells
On February 11, 2020, it became known that ITMO University scientists have found a way to non-invasively release a drug from polymer carriers inside cancer cells.
As reported, the concept is built on the interaction of resonant semiconductor nanoparticles - iron oxide (Fe2O3) with light. They are able to heat locally from laser exposure and convert the resulting light into heat. If such resonant particles modify the shell of polymer containers (capsules), which are used as means for delivering bioactive substances to cells and irradiating them with a laser, then due to heat, deformation of polymer capsules and remote release of drugs in the right place at the right time will occur. The study is published in the journal Laser and Photonics Reviews.
An international team of physicists, chemists and biologists worked on a study in the field of non-invasive opening of capsules with drugs in cancer cells using optical radiation. Scientists at ITMO University were responsible for the synthesis and optical characterization of iron oxide nanoparticles, French colleagues helped to compile a full range of characteristics of the structures of iron oxide, which is used as a semiconductor nanoparticle. Colleagues from China helped visualize the process of opening capsules with the drug, and employees of the First Medical University of St. Petersburg conducted biological experiments to deliver an antitumor drug to primary tumor cells.
As of February 2020, there are antitumor drugs that can effectively fight malignant neoplasms. But, unfortunately, they are aimed not only at affected cells and tissues, but also at healthy ones. Therefore, other approaches are needed to fight cancer. One such approach is the delivery of drugs using micro- and nanoparticles, which creates locally high concentrations of the drug in the tumor zone with minimal systemic concentrations throughout the body.
The idea of delivering drugs using nano- and microparticles is as follows: particles loaded with the drug are injected into the body and accumulated in the tumor zone. In order to non-invasively release the drug, it is necessary to make the carrier particles photosensitive. For this, resonant semiconductor nanoparticles made of iron oxide can be used, which modify polymer containers (capsules). Further, upon irradiation of the modified polymer containers, the iron oxide nanoparticles are heated and the drug is non-invasively released.
Moreover, the advantage of iron oxide is that this material is not only an effective nanohearter, but also a local nanothermometer. That is, by heating the particles, the temperature can be controlled, thereby preventing excessive heating of healthy cells and tissues.
| | We tested our systems for drug delivery of invitro on stem and tumor cells. Stem cells in this experiment were used as a model of healthy cells and tumor cells as a model of diseased cells. As a control, the cells were simply irradiated with a laser with the same parameters. As a result, the action of the antitumor drug was directed against tumor cells when irradiated with a laser, while practically no drug toxicity was observed against healthy cells. Control cells also survived at the end of the experiment, suggesting that tumor cells died as a result of drug release. Thus, light-sensitive systems were created to deliver drugs to cells. narrated by Mikhail Zyuzin | |
The developed systems for delivering drugs to cells can be used as local nanothermometers, making them multifunctional.
| | The nanoparticles in this case act as light-to-heat converters and simultaneously as a thermometer. The fact is that measuring the temperature in traditional ways on such small objects is extremely difficult. For example, there are different techniques that use dyes that burn out and stop shining when a certain temperature is reached. But the problem is that this is not reusable thermometry, and it is also binary, that is, we can only understand: this is above some temperature or below - yes or no. There will be no specific indicators there. And semiconductor nanoparticles effectively absorb light and convert it into heat. Because of this, his frequency of oscillation of the crystal lattice begins to change slightly and otherwise light begins to scatter. From these changes, we can determine how much we heated the particle, and also see this data on the spectrometer. told Georgy Zograf | |
The researchers intend to continue to work and develop the results. In 2021, it is planned to conduct preclinical studies in laboratory animals in vivo.
2019
Gene Surgery will receive 125 million rubles. for the development of a gene therapy anti-tumor drug "AntionkoRAN-M"
On December 25, 2019, RVC announced that the interdepartmental working group for the implementation of the National Technological Initiative approved support for the project for the development of a gene therapy antitumor drug "AntionkoRAN-M" as part of the road map of NTI Helsnet. Read more here.
Biocad presented the results of clinical trials of the drug for the treatment of melanoma - Prolgolimab
On June 25, 2019, Biocad presented the results of clinical studies of the original drug for the therapy of melanoma. Read more here.
Japan first approves Roche drug for personalized cancer therapy
On June 19, 2019, it became known that Japan became the first country in the world to approve the drug of the Swiss company Roche for personalized therapy of malignant neoplasms Rozlytrek (entrectinib). The Ministry of Health, Labor and Social Welfare (MHLW) approved the drug for medical use based on the results of the second phase of clinical trials (CI), in which it showed effectiveness in the treatment of ten different types of cancer. Read more here.
Increase in the number of patients treated with bevacizumab by 300%
The number of cancer patients in Russia who received bevacizumab therapy has increased by 293% over the past 3 years, and the cost of treatment has decreased by 72%. This was reported on June 13, 2019 by the Biocad company. In general, according to the estimates of representatives of "Biocad," the release by the company of the drug "Avegra," the domestic biosimilar bevacizumab, has made it possible since 2015 to triple the availability of targeted therapy for Russian patients. In 2018, according to the company's calculations, 7,678 people received treatment based on domestic bevacizumab. Read more here.
2018
Cancer drugs are the main source of income for pharmaceutical companies
Cancer drugs in 2018 brought in $123 billion in revenue to pharmaceutical companies - with total revenues of 864 billion.
Biocad to invest $26 million in cancer drug infrastructure
FSBI "National Medical Research Center named after V.A. Almazov" and biotechnological company Biocad on May 24, 2018 signed an agreement on cooperation and performance of joint research work.
In particular, as told in Biocad, the partners intend to conduct joint scientific research on adaptive immunotherapy (CAR T-cell therapy). The method of CAR T-cell therapy is based on the introduction of genetically modified own T-lymphocytes to the patient, providing recognition of tumor cells.
In addition, Ministry of Health Russia together with Biocad, it plans to build a clinic on the basis of the National Medical Research Center named after Almazov, in which patients suffering from cancer will be treated with the help of personalized biomedical cell products. Biocad's gene therapy infrastructure is estimated at $26 million, which the company plans to invest over two years.
The cooperation agreement was signed by the head of the Federal Center named after V.A. Almazov Evgeny Shlyakhto and the general director of the biotechnological company Biocad Dmitry Morozov with the participation of the Deputy Minister of Health of the Russian Federation Sergei Krayevoy.
According to the representative of the Ministry of Health, the signing of an agreement on joint research between a state and commercial institution in the most advanced area of creating individual antitumor biomedical cell products will allow the country to make a breakthrough in the development and promotion of innovative methods of treating cancer, strengthen the competitiveness of the industry in the global market, as well as provide Russian cancer patients with modern and effective means of therapy.
| | We have all seen the success of our health care in reducing mortality from cardiological diseases, the next task is to provide a wide range of patients suffering from cancer with modern and effective therapy, - said Dmitry Morozov. | |
According to the assessment of the general director of Biocad, the cost of manufacturing individual drugs per patient will not exceed 16 million rubles, which is two times cheaper than in Western clinics. In addition, the patient will not need additional therapy for three years, but only periodic follow-up with the doctor.
Evgeny Shlyakhto, for his part, pointed to the second aspect of the agreement with the innovative biotechnology company - to find approaches to the education and training of Russian doctors so that they are guided in modern areas of science, such as synthetic biology.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |